Uncategorized

Skye and Redx form new entity with $125M to advance fibrosis assets

Published

on

Skye Bioscience has entered into an agreement to combine with privately held fibrotic disease biotech Redx Pharma in a deal that will net $125 million in financing for the new public company, called Fibrx Therapeutics.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version